Cullinan Oncology Llc Stock Market Value
| CGEM Stock | USD 13.09 0.32 2.51% |
| Symbol | Cullinan |
Cullinan Oncology LLC Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cullinan Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cullinan Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cullinan Oncology.
| 10/29/2024 |
| 11/28/2024 |
If you would invest 0.00 in Cullinan Oncology on October 29, 2024 and sell it all today you would earn a total of 0.00 from holding Cullinan Oncology LLC or generate 0.0% return on investment in Cullinan Oncology over 30 days. Cullinan Oncology is related to or competes with Ikena Oncology, Eliem Therapeutics, HCW Biologics, Tempest Therapeutics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-on... More
Cullinan Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cullinan Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cullinan Oncology LLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 17.85 | |||
| Value At Risk | (7.24) | |||
| Potential Upside | 5.88 |
Cullinan Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cullinan Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cullinan Oncology's standard deviation. In reality, there are many statistical measures that can use Cullinan Oncology historical prices to predict the future Cullinan Oncology's volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.73) | |||
| Total Risk Alpha | (1.04) | |||
| Treynor Ratio | (0.24) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cullinan Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cullinan Oncology LLC Backtested Returns
Cullinan Oncology LLC secures Sharpe Ratio (or Efficiency) of -0.16, which signifies that the company had a -0.16% return per unit of risk over the last 3 months. Cullinan Oncology LLC exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cullinan Oncology's Mean Deviation of 2.85, standard deviation of 3.62, and Risk Adjusted Performance of (0.1) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.04, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cullinan Oncology will likely underperform. At this point, Cullinan Oncology LLC has a negative expected return of -0.56%. Please make sure to confirm Cullinan Oncology's kurtosis, and the relationship between the maximum drawdown and day median price , to decide if Cullinan Oncology LLC performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.24 |
Weak predictability
Cullinan Oncology LLC has weak predictability. Overlapping area represents the amount of predictability between Cullinan Oncology time series from 29th of October 2024 to 13th of November 2024 and 13th of November 2024 to 28th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cullinan Oncology LLC price movement. The serial correlation of 0.24 indicates that over 24.0% of current Cullinan Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.24 | |
| Spearman Rank Test | 0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 1.15 |
Cullinan Oncology LLC lagged returns against current returns
Autocorrelation, which is Cullinan Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cullinan Oncology's stock expected returns. We can calculate the autocorrelation of Cullinan Oncology returns to help us make a trade decision. For example, suppose you find that Cullinan Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Cullinan Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cullinan Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cullinan Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cullinan Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
Cullinan Oncology Lagged Returns
When evaluating Cullinan Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cullinan Oncology stock have on its future price. Cullinan Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cullinan Oncology autocorrelation shows the relationship between Cullinan Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in Cullinan Oncology LLC.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Cullinan Oncology Correlation, Cullinan Oncology Volatility and Cullinan Oncology Alpha and Beta module to complement your research on Cullinan Oncology. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Cullinan Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.